Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556763 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
A Phase 1 study, sponsored by FORUM Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01556763 is a Phase 1 study that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT01556763, a Phase 1 study, has completed, sponsored by FORUM Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo when given with the patient's usual antipsychotic medication.
Interventions
- DRUG Placebo
- DRUG EVP-6124 (0.3 mg/day)
- DRUG EVP-6124 (1.0 mg/day)
- DRUG Antipsychotic therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01556763
The ClinicalTrials.gov registry entry for NCT01556763 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FORUM Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01556763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01556763 about?
NCT01556763 is a clinical study titled "Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia". This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo when given with the patient's usual antipsychotic medication.
What is the current status of trial NCT01556763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2008-04. Estimated completion is 2008-08.
What interventions are being tested in trial NCT01556763?
The interventions under investigation include: Placebo (DRUG), EVP-6124 (0.3 mg/day) (DRUG), EVP-6124 (1.0 mg/day) (DRUG), Antipsychotic therapy (DRUG).
Who is sponsoring clinical trial NCT01556763?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.